iCare: Evaluating the Usability of iPad Minis in the Clinical Setting

Publish Date: 
Wednesday, January 7, 2015

Technology is great…when it works. This phrase comes to mind every time technology is supposed to enhance an experience and a malfunction causes that experience to cease. We know that technology should have the capacity to transform our lives, including our lives as HIV care providers. But in order for it to do so, it has to work. It has to be usable (i.e. easy, reliable, and fast). While iPad Minis have been on the market for several years now, a review of the literature yielded no current studies to examine their usability or effectiveness in clinical use.

The HIV/AIDS Treatment Cascade in the U.S. Virgin Islands: Testing and Diagnosis in Paradise

Publish Date: 
Wednesday, December 3, 2014

virgin islandsQuite often when you think about the U.S. Virgin Islands (USVI), you envision a beautiful vacation on the beach drinking Pina Coladas, eating local food and listening to the sounds of island music. Although the Virgin Islands are truly paradise vacation spots, they are not free from the impact of HIV/AIDS. The three islands of St. Croix, St. Thomas, and St. John are unique and face their own challenges with testing, diagnosis, and treatment.

The National Quality Center Highlights Innovative Tools as it Celebrates its 10-Year Anniversary

Publish Date: 
Tuesday, December 16, 2014
In order to curtail new HIV infections and better reach—and engage—people living with HIV into care, providers have to evolve in the way that they do business. Performance measures are important indicators in ensuring effective provider practices and high-quality HIV care.
For the last 10 years the National Quality Center (NQC) has provided technical assistance to support Ryan White HIV/AIDS Program grantees by creating innovative services to meet their unique needs.

Connecting to Care: How Ryan White Grantees are Engaging Patients with the ACA

Publish Date: 
Friday, November 14, 2014

It’s that time of the year again: open enrollment season within the Health Insurance Marketplace!

Ryan White HIV/AIDS Program grantees are actively engaged in Affordable Care Act (ACA) activities, connecting patients with health insurance—many for the first time in their lives. The transformative power of health insurance cannot be overstated, particularly for individuals with a chronic disease like HIV and whom often times suffer from a myriad of other health conditions.

Drug-Drug Interactions: Etravirine with Dolutegravir or Atazanavir

Publish Date: 
Friday, October 17, 2014

New data show that etravirine (ETR) substantially lowers plasma concentrations of dolutegravir (DTG) (DTG Cmin decreased 88%, AUC decreased 71%). This effect is lessened by coadministration of ritonavir-boosted PIs: the combination of ETR + DTG + darunavir/ritonavir (600/100 mg BID) resulted in a decrease in DTG Cmin and AUC of 37% and 25%, respectively. When ETR + DTG were given with lopinavir/ritonavir, the DTG Cmin and AUC were increased slightly. No data are available for the interaction with atazanavir/ritonavir.

Elvitegravir Approved as an Independent Medication

Publish Date: 
Friday, September 26, 2014
Elvitegravir is an HIV integrase inhibitor that requires pharmacokinetic enhancement with cobicistat or ritonavir. Since 2012 it has been available in a coformulation with cobicistat, tenofovir, and emtricitabine (Stribild) for treatment-naïve adults. This month the FDA approved elvitegravir as an independent medication, for use in in combination with a ritonavir-boosted protease inhibitor (and other ARVs) in treatment-experienced adults. Its brand name is Vitekta.

Cobicistat approved as PK booster

Publish Date: 
Friday, September 26, 2014
Cobicistat, a CYP3A inhibitor, has been approved by the FDA to be used as a pharmacokinetic booster for atazanavir and once-daily darunavir. Thus, it can be used as an alternative to ritonavir in these combinations. It already is available as a PK enhancer of elvitegravir in the elvitegravir/cobicistat/tenofovir/emtricitabine coformulation (Stribild). Cobicistat’s brand name is Tybost.

New Fixed-Dose Combination Pill: Dolutegravir + Abacavir + Lamivudine

Publish Date: 
Friday, September 26, 2014
The FDA has approved the coformulation of the integrase inhibitor dolutegravir (50 mg) with the NRTIs abacavir (600 mg) and lamivudine (300 mg); its brand name is Triumeq. Triumeq is the first single-pill combination that does not include tenofovir.

Project B.R.I.E.F – An Educational Video Intervention for HIV Prevention

Publish Date: 
Wednesday, September 10, 2014

Project B.R.I.E.F. (Behavior intervention, Rapid HIV test, Innovative video, Efficient cost and health care savings, and Facilitated seamless linkage to outpatient HIV care) began in 2003 as a collaboration between two physicians looking to make a difference in the Bronx, NY community. As attending physicians at Jacobi Medical Center, both Dr. Jason Leider and I experienced first-hand the impact of HIV on the Bronx, a community with one of the highest rates of HIV prevalence in the nation.


Subscribe to Sharespot RSS feed